Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04003610
Recruitment Status : Terminated (The reason this study was terminated was due to a business decision. There were no safety concerns that contributed to this decision.)
First Posted : July 1, 2019
Last Update Posted : October 6, 2021
Information provided by (Responsible Party):
Incyte Corporation

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : April 18, 2021
Actual Study Completion Date : April 18, 2021